BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study-Reference-Cited by-同舟云学术

BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

Published:2019-10 Issue: Volume:30 Page:v203
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mettu N.B.,Twohy E.,Ou F.-S.,Halfdanarson T.R.,Lenz H.J.,Breakstone R.,Boland P.M.,Crysler O.,Wu C.,Grothey A.,Nixon A.B.,Bolch E.,Niedzwiecki D.,Fruth B.,Schweitzer B.,Elsing A.,Hurwitz H.,Fakih M.G.,Bekaii-Saab T.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz246.011/30083100/mdz246.011.pdf

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating through novelties concerning mCRC treatment—the role of immunotherapy, chemotherapy, and targeted therapy in mCRC;Frontiers in Surgery;2024-06-14

2. Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial;Clinical Cancer Research;2024-05-10

3. Comparative effectiveness of immunotherapy and chemotherapy in patients with metastatic colorectal cancer stratified by microsatellite instability status;World Journal of Clinical Oncology;2024-04-24

4. Absolute increase in tumour size can improve the metric evaluating disease progression in metastatic colorectal cancer;2024-02-06

5. The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review;The Oncologist;2024-02-03